Flibanserin

Flibanserin

SCHEMBL247579

O=c1[nH]c2ccccc2n1CCN1CCN(c2cccc(C(F)(F)F)c2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 5/20 1.00
ABCB11 O95342 1/20 1.00
ADRA2A P08913 1/20 1.00
ADORA3 P0DMS8 1/20 1.00
CHRM1 P11229 1/20 1.00
DRD1 P21728 1/20 1.00
TBXA2R P21731 1/20 1.00
SLC6A4 P31645 1/20 1.00
ADRA1A P35348 1/20 1.00
OPRM1 P35372 1/20 1.00
DRD3 P35462 1/20 1.00
KCNH2 Q12809 1/20 1.00
HTR7 P34969 8/20 0.71
SIGMAR1 Q99720 2/20 0.58
NPSR1 Q6W5P4 2/20 0.58
DRD2 P14416 3/20 0.57
HTR2A P28223 2/20 0.57
LMNA P02545 2/20 0.55
TP53 P04637 2/20 0.55
MAPT P10636 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Flibanserin SCHEMBL30249132 1.00 HTR1A (1.00) HTR1AABCB11ADRA2AADORA3CHRM1
Flibanserin SCHEMBL29399513 1.00 HTR1A (1.00) HTR1AABCB11ADRA2AADORA3CHRM1
Flibanserin SCHEMBL19743166 0.99 HTR1A (0.98) HTR1AABCB11ADRA2AADORA3CHRM1
Flibanserin SCHEMBL19743151 0.99 HTR1A (0.98) HTR1AABCB11ADRA2AADORA3CHRM1
Flibanserin SCHEMBL563586 0.99 HTR1A (0.98) HTR1AABCB11ADRA2AADORA3CHRM1
Flibanserin SCHEMBL2526226 0.99 HTR1A (0.98) HTR1AABCB11ADRA2AADORA3CHRM1
SCHEMBL8123196 0.96 HTR1A (0.92) HTR1AABCB11ADRA2AADORA3CHRM1
Flibanserin SCHEMBL2521706 0.95 HTR1A (0.90) HTR1AABCB11ADRA2AADORA3CHRM1
Flibanserin SCHEMBL2525812 0.95 HTR1A (0.90) HTR1AABCB11ADRA2AADORA3CHRM1
SCHEMBL8121051 0.94 HTR1A (0.88) HTR1AABCB11ADRA2AADORA3CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2633 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12629363-B2 Prophylaxis and treatment of angioedema PHARVARIS GMBH (CH) 2026-05-19 US claimed
US-20260069593-A1 METHODS FOR TREATING CANCER AMGEN INC (US) 2026-03-12 US claimed
EP-4633638-A1 TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) Luminous Mind Inc. (US) 2025-10-22 EP claimed
US-20250295611-A1 METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS TESSELLATE THERAPEUTICS INC (US) 2025-09-25 US claimed
WO-2025111482-A1 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS BEXSON BIOMEDICAL, INC. (US) 2025-05-30 WO claimed
WO-2025098307-A1 USE OF 3-[(BENZO[D][1,3]DIOXOLAN-4-YL)-OXY]-3-ARYL PROPYLAMINE COMPOUND IN PREPARATION OF DRUG FOR TREATING SEXUAL DYSFUNCTION 江苏恩华药业股份有限公司 2025-05-15 WO claimed
US-20250152591-A1 TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS KURA ONCOLOGY INC (US) 2025-05-15 US claimed
EP-4547250-A1 METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS Terran Biosciences Inc. (US) 2025-05-07 EP claimed
CN-115803088-B Cyclobenzaprine treatment of sexual dysfunction 通尼克斯医药控股公司 2025-03-21 CN claimed
US-20250049748-A1 ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE TERRAN BIOSCIENCES INC (US) 2025-02-13 US claimed
WO-2003014079-A1 STABLE POLYMORPH OF FLIBANSERIN, TECHNICAL PROCESS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS BIDACHEM S.P.A (IT) 2003-02-20 WO claimed
EP-1267878-A2 COMPOUNDS WITH 5-HT ACTIVITY USEFUL FOR CONTROLLING VISUAL FIELD LOSS Alcon, Inc (CH) 2003-01-02 EP claimed
EP-1263504-A2 COMPOUNDS WITH 5-HT1A ACTIVITY USEFUL FOR TREATING DISORDERS OF THE OUTER RETINA Alcon Inc. (CH) 2002-12-11 EP claimed
WO-2001070222-A2 COMPOUNDS WITH 5-HT1A ACTIVITY USEFUL FOR TREATING DISORDERS OF THE OUTER RETINA ALCON INC. (CH) 2001-09-27 WO claimed
WO-2001070230-A2 COMPOUNDS WITH 5-HT ACTIVITY USEFUL FOR CONTROLLING VISUAL FIELD LOSS ALCON, INC. (CH) 2001-09-27 WO claimed
EP-0526434-B1 Benzimidazolone derivatives as 5-HT1A and 5-HT2 antagonists BOEHRINGER INGELHEIM ITALIA (IT) 2000-04-19 EP claimed
WO-2000006160-A1 TREATING DEPRESSION WITH A COMBINATION OF FLUOXETINE (PROZAC), PINDOLOL (VISKEN) AND BUSPIRONE (BUSPAR) SANOFI-SYNTHELABO (FR) 2000-02-10 WO claimed
WO-1999013879-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING A MONOAMINE OXYDASE INHIBITOR AND THEIR USE IN THERAPY SANOFI-SYNTHELABO (FR) 1999-03-25 WO claimed
WO-1993003016-A1 BENZIMIDAZOLONE DERIVATIVES AS 5-HT1A AND 5-HT2 ANTAGONISTS BOEHRINGER INGELHEIM ITALIA S.P.A. (IT) 1993-02-18 WO claimed
EP-0526434-A1 Benzimidazolone derivatives as 5-HT1A and 5-HT2 antagonists BOEHRINGER INGELHEIM ITALIA S.p.A. (IT) 1993-02-03 EP claimed